title: Development of novel entry inhibitors targeting emerging viruses.
abstract: Emerging viral diseases pose a unique risk to public health, and thus there is a need to develop therapies. A current focus of funding agencies, and hence research, is the development of broad-spectrum antivirals, and in particular, those targeting common cellular pathways. The scope of this article is to review screening strategies and recent advances in this area, with a particular emphasis on antivirals targeting the step of viral entry for emerging lipid-enveloped viruses such as Ebola virus and SARS-coronavirus.
authors.affiliation: Blood Systems Research Institute and Department of Laboratory Medicine, University of California, San Francisco, 270 Masonic Avenue, San Francisco, CA 94118, USA.
authors.forename: Yanchen
authors.initials: Y
authors.lastname: Zhou
authors.forename: Graham
authors.initials: G
authors.lastname: Simmons
mesh_terms: D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D021821:Communicable Diseases, Emerging / Q000821:virology*; D057166:High-Throughput Screening Assays; D054884:Host-Pathogen Interactions / Q000187:drug effects; D011991:Receptors, Virus / Q000187:drug effects / Q000502:physiology; D053585:Virus Attachment / Q000187:drug effects; D053586:Virus Internalization / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D011991:Receptors, Virus